Discovery of new 7-azaindole derivatives as CSN5 inhibitors with in vitro antitumor activity against triple-negative breast cancer.
COP9 signalosome subunit 5 (CSN5) exerts critical deneddylase activity and is frequently overexpressed in triple-negative breast cancer (TNBC), representing a compelling antitumour target. However, to date, only a limited number of inhibitors targeting CSN5 have been reported, and none of them have advanced into clinic...